DOCSLIB.ORG

Forxiga, INN-Dapagliflozin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Forxiga, INN-Dapagliflozin ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Forxiga 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin. Excipient with known effect Each 5 mg tablet contains 25 mg of lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Yellow, biconvex, 0.7 cm diameter round, film-coated tablets with “5” engraved on one side and “1427” engraved on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Type 2 diabetes mellitus Forxiga is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. Type 1 diabetes mellitus Forxiga is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. Heart failure Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Chronic kidney disease Forxiga is indicated in adults for the treatment of chronic kidney disease. 2 4.2 Posology and method of administration Posology Type 2 diabetes mellitus The recommended dose is 10 mg dapagliflozin once daily. When dapagliflozin is used in combination with insulin or an insulin secretagogue, such as a sulphonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycaemia (see sections 4.5 and 4.8). Type 1 diabetes mellitus Treatment with Forxiga is to be initiated and supervised by specialists in type 1 diabetes. The recommended dose is 5 mg once daily. Dapagliflozin must only be administered as an adjunct to insulin. Before initiating treatment with dapagliflozin Risk factors for diabetic ketoacidosis (DKA) should be assessed (see section 4.4). It should be ensured that ketone levels are normal. If ketones are elevated (blood beta- hydroxybutyrate reading greater than 0.6 mmol/L or urine ketones one plus (+)), treatment with dapagliflozin should not be started until the ketone levels are normal (see section 4.4). It should be ensured that the patient demonstrates the ability to monitor ketone levels. It is recommended that patients obtain several baseline ketone levels over one to two weeks prior to initiation of dapagliflozin therapy, and patients should become familiar with how their behaviours and circumstances affect their ketone levels. Patients should be informed, in a dedicated education session, on the risk of DKA, how to recognise DKA risk factors, signs or symptoms, how and when to monitor ketone levels and what actions to take at elevated ketone readings (see section 4.4). Correction of volume depletion prior to initiation of dapagliflozin is recommended in patients with this condition (see section 4.4). In order to avoid hypoglycaemia with the first dose of dapagliflozin, a 20% reduction in the first mealtime bolus insulin may be considered. Subsequent bolus doses should be adjusted individually based on blood glucose results. No reduction in basal insulin is recommended when initiating dapagliflozin. Subsequently, basal insulin should be adjusted based on blood glucose results. When needed, insulin dose reduction should be done cautiously to avoid ketosis and DKA. Ketone monitoring during treatment During the initial one to two weeks of treatment with dapagliflozin, ketones should be monitored on a regular basis, then the frequency of ketone level testing should be individualised, according to the patient's lifestyle and/or risk factors (see section 4.4). Patients should be informed about what actions to take if ketone levels are elevated. The recommended actions are listed in Table 1. Measurement of blood ketone levels is preferred to urine. Table 1 Clinical stage Blood ketone (beta- Urine ketone Actions hydroxybutyrate) Ketonaemia 0.6-1.5 mmol/L Trace or Small The patient may need to take + extra insulin and drink water. The patient should measure blood glucose and consider taking extra carbohydrates if the 3 glucose levels are normal or low. Ketone levels should be measured again after two hours. The patient should immediately seek medical advice and stop taking dapagliflozin if levels persist and symptoms present. Impending DKA > 1.5-3.0 mmol/L Moderate The patient should immediately ++ seek medical advice and stop taking dapagliflozin. The patient may need to take extra insulin and drink water. The patient should measure blood glucose and consider taking extra carbohydrates if the glucose levels are normal or low. Ketone levels should be measured again after two hours. Probable DKA > 3.0 mmol/L Large to very The patient should go to large emergency department without +++ / ++++ delay and stop taking dapagliflozin. The patient may need to take extra insulin and drink water. The patient should measure blood glucose and consider taking extra carbohydrates if the glucose levels are normal or low. Heart failure The recommended dose is 10 mg dapagliflozin once daily. In the DAPA-HF study, dapagliflozin was administered in conjunction with other heart failure therapies (see section 5.1). Chronic kidney disease The recommended dose is 10 mg dapagliflozin once daily. In the DAPA-CKD study, dapagliflozin was administered in conjunction with other chronic kidney disease therapies (see section 5.1). Special populations Renal impairment No dose adjustment is required based on renal function. 4 Due to limited experience, it is not recommended to initiate treatment with dapagliflozin in patients with GFR < 25 mL/min. In patients with diabetes mellitus, the glucose lowering efficacy of dapagliflozin is reduced when the glomerular filtration rate (GFR) is < 45 mL/min, and is likely absent in patients with severe renal impairment. Therefore, if GFR falls below 45 mL/min, additional glucose lowering treatment should be considered in patients with diabetes mellitus if further glycaemic control is needed (see sections 4.4, 4.8, 5.1 and 5.2). Hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, the dose may be increased to 10 mg when indicated (see sections 4.1 of the 10 mg SmPC, 4.4 and 5.2). Patients with type 1 diabetes mellitus Forxiga 10 mg is not recommended for the treatment of heart failure or chronic kidney disease, in patients with type 1 diabetes mellitus (see section 4.4). Elderly (≥ 65 years) No dose adjustment is recommended based on age. Paediatric population The safety and efficacy of dapagliflozin in children aged 0 to < 18 years have not yet been established. No data are available. Method of administration Forxiga can be taken orally once daily at any time of day with or without food. Tablets are to be swallowed whole. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4 Special warnings and precautions for use Renal impairment Due to limited experience, it is not recommended to initiate treatment with dapagliflozin in patients with GFR < 25 mL/min. The glucose lowering efficacy of dapagliflozin is dependent on renal function, and is reduced in patients with GFR < 45 mL/min and is likely absent in patients with severe renal impairment (see sections 4.2, 5.1 and 5.2). In one study in patients with type 2 diabetes mellitus with moderate renal impairment (GFR < 60 mL/min), a higher proportion of patients treated with dapagliflozin had adverse reactions of increase in creatinine, phosphorus, parathyroid hormone (PTH) and hypotension, compared with placebo. Hepatic impairment There is limited experience in clinical studies in patients with hepatic impairment. Dapagliflozin exposure is increased in patients with severe hepatic impairment (see sections 4.2 and 5.2). 5 Use in patients at risk for volume depletion and/or hypotension Due to its mechanism of action, dapagliflozin increases diuresis which may lead to the modest decrease in blood pressure observed in clinical studies (see section 5.1). It may be more pronounced in patients with very high blood glucose concentrations. Caution should be exercised in patients for whom a dapagliflozin-induced drop in blood pressure could pose a risk, such as patients on anti-hypertensive therapy with a history of hypotension or elderly patients. In case of intercurrent conditions that may lead to volume depletion (e.g. gastrointestinal illness), careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit and electrolytes) is recommended. Temporary interruption of treatment with dapagliflozin is recommended for patients who develop volume depletion until the depletion is corrected (see section 4.8). Diabetic ketoacidosis Sodium-glucose co-transporter 2 (SGLT2) inhibitors should be used with caution in patients with increased risk of DKA. Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g. type 1 diabetes patients, type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery or alcohol abuse. The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness.
Load more

Recommended publications
  • Fixed Dose Combination of Voglibose & Repaglinide in the Management
    Clinical Group Global Journal of Obesity, Diabetes and Metabolic Syndrome ISSN: 2455-8583 DOI CC By Arif Faruqui* Research Article Medical Services Department, Medley Pharmaceuticals Limited, Mumbai, India Fixed Dose Combination of Voglibose Dates: Received: 09 August, 2017; Accepted: 26 August, 2017; Published: 28 August, 2017 & Repaglinide in the Management of *Corresponding author: Arif Faruqui, Medical Services Department, Medley Pharmaceuticals Limited, Mumbai, Postprandial Hyperglycemia in Indian India, E-mail: Subjects Keywords: T2DM; Postprandial hyperglycemia; Voglibose; Repaglinide https://www.peertechz.com Abstract To evaluate the effi cacy and tolerability of fi xed dose combination of voglibose and repaglinide in postprandial hyperglycemia (PPHG) in Indian subjects. A non-randomized, open labeled, non-comparative, single-centric, study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fi xed dose combination of voglibose 0.3mg and repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) and postprandial blood glucose (PPBG) was performed at baseline and at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced signifi cantly {-61.67mg/dl (95% confi dence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a signifi cant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confi dence interval -61.25 to -23.02 P value <0.0001)} at end of day 30.
    [Show full text]
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • Dapagliflozin – Structure, Synthesis, and New Indications
    Pharmacia 68(3): 591–596 DOI 10.3897/pharmacia.68.e70626 Review Article Dapagliflozin – structure, synthesis, and new indications Stefan Balkanski1 1 Bulgarian Pharmaceutical Union, Sofia, Bulgaria Corresponding author: Stefan Balkanski ([email protected]) Received 24 June 2021 ♦ Accepted 4 July 2021 ♦ Published 4 August 2021 Citation: Balkanski S (2021) Dapagliflozin – structure, synthesis, and new indications. Pharmacia 68(3): 591–596.https://doi. org/10.3897/pharmacia.68.e70626 Abstract Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside with significant effect as glucose-lowering agents, Dapagliflozin also has indication for patients with Heart Failure and Chronic Kidney Disease. This review examines the structure, synthesis, analysis, structure activity relationship and uses of the prod- uct. The studies behind this drug have opened the doors for the new line of treatment – a drug that reduces blood glucoses, decreases the rate of heart failures, and has a positive effect on patients with chronic kidney disease. Keywords Dapagliflozin, SGLT2-inhibitor, diabetes, heart failure Structure of dapagliflozin against diabetes (Lee et al. 2005; Lemaire 2012; Mironova et al. 2017). Embodiments of (SGLT-2) inhibitors include C-glycosides have a remarkable rank in medicinal chemis- dapagliflozin, canagliflozin, empagliflozin and ipragliflozin, try as they are considered as universal natural products shown in Figure 1. It has molecular formula of C24H35ClO9. (Qinpei and Simon 2004). Selective sodium-dependent IUPAC name (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4- glucose cotransporter 2 (SGLT-2) inhibitors are potent ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxa- medicinal candidates of aryl glycosides that are functional ne-3,4,5-triol;(2S)-propane-1,2-diol;hydrate.
    [Show full text]
  • Qtern (Dapagliflozin/Saxagliptin) – New Drug Approval
    Qtern® (dapagliflozin/saxagliptin) – New drug approval • On February 28, 2017, AstraZeneca announced the FDA approval of Qtern (dapagliflozin/saxagliptin) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) who have inadequate control with Farxiga® (dapagliflozin) or who are already treated with dapagliflozin and Onglyza® (saxagliptin). • Qtern is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, and it should only be used in patients who tolerate 10 mg of dapagliflozin. • Qtern combines two anti-hyperglycemic agents, dapagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. • The efficacy of Qtern was evaluated in a study of 315 T2DM patients. Patients were randomized to saxagliptin or placebo, in combination with dapagliflozin and metformin. — Patients treated with add-on saxagliptin therapy had significantly greater reductions in HbA1c from baseline vs. the placebo group (-0.5% vs. -0.2%, respectively; difference between groups in HbA1c: -0.4%, p < 0.0001). — The proportion of patients achieving HbA1c < 7% at week 24 was 35.3% in the saxagliptin group vs. 23.1% in the placebo group. • Qtern is contraindicated in patients with a history of a serious hypersensitivity reaction to dapagliflozin or to saxagliptin (eg, anaphylaxis, angioedema or exfoliative skin conditions), and in patients with moderate to severe renal impairment (eGFR < 45 mL/min/1.73 m2), end-stage renal disease, or on dialysis. • Warnings and precautions of Qtern include pancreatitis, heart failure, hypotension, ketoacidosis, acute kidney injury and impairment in renal function, urosepsis and pyelonephritis, hypoglycemia with concomitant use of insulin or insulin secretagogues, genital mycotic infections, increases in low- density lipoprotein cholesterol, bladder cancer, severe and disabling arthralgia, and bullous pemphigoid.
    [Show full text]
  • The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves B-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat
    1521-0103/350/3/657–664$25.00 http://dx.doi.org/10.1124/jpet.114.213454 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 350:657–664, September 2014 Copyright ª 2014 by The American Society for Pharmacology and Experimental Therapeutics The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves b-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat Henrik H. Hansen, Jacob Jelsing, Carl Frederik Hansen, Gitte Hansen, Niels Vrang, Michael Mark, Thomas Klein, and Eric Mayoux Gubra, Hørsholm, Denmark (H.H.H., J.J., C.F.H., G.H., N.V.); and Boehringer Ingelheim Pharma, Biberach, Germany (M.M., T.K., E.M.) Received January 22, 2014; accepted July 2, 2014 Downloaded from ABSTRACT Type 2 diabetes is characterized by impaired b-cell function at week 8 of treatment compared with week 4, those of empagliflozin associated with progressive reduction of insulin secretion and remained stable throughout the study period. Similarly, empagliflozin b -cell mass. Evidently, there is an unmet need for treatments improved glucose tolerance and preserved insulin secretion jpet.aspetjournals.org with greater sustainability in b-cell protection and antidiabetic after both 4 and 8 weeks of treatment. These effects were efficacy. Through an insulin and b cell–independent mechanism, reflected by less reduction in b-cell mass with empagliflozin or empagliflozin, a specific sodium glucose cotransporter type 2 liraglutide at week 4, whereas only empagliflozin showed b-cell (SGLT-2) inhibitor, may potentially provide longer efficacy. This sparing effects also at week 8. Although this study cannot be study compared the antidiabetic durability of empagliflozin treat- used to dissociate the absolute antidiabetic efficacy among ment (10 mg/kg p.o.) against glibenclamide (3 mg/kg p.o.) and the different mechanisms of drug action, the study demon- liraglutide (0.2 mg/kg s.c.) on deficient glucose homeostasis and strates that empagliflozin exerts a more sustained improve- b-cell function in Zucker diabetic fatty (ZDF) rats.
    [Show full text]
  • 202293Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202293Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Office of Medication Error Prevention and Risk Management Final Risk Evaluation and Mitigation Strategy (REMS) Review Date: December 20, 2013 Reviewer(s): Amarilys Vega, M.D., M.P.H, Medical Officer Division of Risk Management (DRISK) Team Leader: Cynthia LaCivita, Pharm.D., Team Leader DRISK Drug Name(s): Dapagliflozin Therapeutic Class: Antihyperglycemic, SGLT2 Inhibitor Dosage and Route: 5 mg or 10 mg, oral tablet Application Type/Number: NDA 202293 Submission Number: Original, July 11, 2013; Sequence Number 0095 Applicant/sponsor: Bristol-Myers Squibb and AstraZeneca OSE RCM #: 2013-1639 and 2013-1637 *** This document contains proprietary and confidential information that should not be released to the public. *** Reference ID: 3426343 1 INTRODUCTION This review documents DRISK’s evaluation of the need for a risk evaluation and mitigation strategy (REMS) for dapagliflozin (NDA 202293). The proposed proprietary name is Forxiga. Bristol-Myers Squibb and AstraZeneca (BMS/AZ) are seeking approval for dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). Bristol-Myers Squibb and AstraZeneca did not submit a REMS or risk management plan (RMP) with this application. At the time this review was completed, FDA’s review of this application was still ongoing. 1.1 BACKGROUND Dapagliflozin. Dapagliflozin is a potent, selective, and reversible inhibitor of the human renal sodium glucose cotransporter 2 (SGLT2), the major transporter responsible for renal glucose reabsorption.
    [Show full text]
  • Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including
    Kidney360 Publish Ahead of Print, published on February 1, 2021 as doi:10.34067/KID.0000412021 Real-life prescribing of SGLT2 inhibitors: How to handle the other medications, including glucose-lowering drugs and diuretics David Lam1 and Aisha Shaikh1,2 1Icahn School of Medicine at Mount Sinai, Dept. of Medicine, New York, NY 2James J. Peters VA Medical Center, Dept. of Medicine, Bronx, NY Corresponding Author: Aisha Shaikh, MD James J. Peters VA Medical Center 130 w. Kingsbridge Road Bronx, NY – 10468 Email: [email protected] Phone: 718-584-9000, Ext# 6630 Copyright 2021 by American Society of Nephrology. Introduction Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as an effective therapy for improving outcomes in diabetic and non-diabetic kidney disease (1, 2). Clinical trials have demonstrated the benefits of SGLT2is for secondary prevention of adverse cardiovascular (CV) effects in patients with established atherosclerotic disease and/or heart failure with reduced ejection fraction (3-7). It is imperative for clinicians to assess the use of SGLT2is in medically eligible patients and prescribe these agents when appropriate. Despite the overwhelming evidence of the benefits of SGLT2i therapy, the prescription rate remains dismally low particularly among patients most likely to benefit from cardiorenal protective effects (8). Several potential factors contribute to low SGLT2i prescription rate including prescriber hesitancy, treatment inertia and high drug cost. In this article, we review clinical indications for SGLT2i use, therapeutic and adverse effects, and our approach to handling concomitant medications. Clinical indications for SGLT2i Use 1. Type 2 diabetes mellitus (T2DM) and albuminuric kidney disease (albuminuria of ≥ 200 mg/gram of creatinine plus eGFR of 25 – 90 ml/min/1.73 m2).
    [Show full text]
  • Impact of Voglibose on the Pharmacokinetics of Dapagliflozin
    Diabetes Ther (2013) 4:41–49 DOI 10.1007/s13300-012-0016-5 ORIGINAL RESEARCH Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes Akira Imamura • Masahito Kusunoki • Shinya Ueda • Nobuya Hayashi • Yasuhiko Imai To view enhanced content go to www.diabetestherapy-open.com Received: September 24, 2012 / Published online: January 10, 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com ABSTRACT glucose reabsorption. This study was performed to assess the effect of the oral antidiabetic agent Introduction: Dapagliflozin is an orally voglibose [0.2 mg thrice daily (t.i.d.)] at steady- administered selective sodium-glucose state, on the pharmacokinetics, safety and cotransporter 2 (SGLT2) inhibitor under tolerability of dapagliflozin administered as a development for the treatment of type 2 single oral dose (10 mg) to Japanese patients diabetes mellitus (T2DM). Dapagliflozin lowers with T2DM. blood glucose through a reduction in renal Methods: This was an open-label, multi-center, ClinicalTrials.gov: #NCT01055652. drug–drug interaction study. A single oral dose of dapagliflozin (10 mg) was administered to 22 A. Imamura (&) Japanese patients with T2DM in the presence Moriya Keiyu Hospital, 980-1, Tatuzawa, and absence of voglibose (0.2 mg t.i.d.). Serial Moriya City, Ibaraki 302-0118, Japan e-mail: [email protected] blood samples were collected before and at regular prespecified intervals after each M. Kusunoki The Institute for Rehabilitation Studies, Kobe dapagliflozin dose to determine dapagliflozin International University, 9-1-6 Koyocho-naka, plasma concentrations and to evaluate Higashinada-ku, Kobe-city, Hyogo 658-0032, Japan pharmacokinetic parameters.
    [Show full text]
  • SGLT2) Inhibitors (Gliflozins) in Adults with Type 2 Diabetes (T2DM
    Sodium-glucose cotransporter-2 (SGLT2) inhibitors (Gliflozins) in Adults with Type 2 Diabetes (T2DM) There are currently four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ertugliflozin) licensed in the UK for the management of adults with T2DM. No head to head trials between the SGLT2 inhibitors have been conducted. As at December 2019, clinical outcome data is available for three of the four SGLT2 inhibitors around their cardiovascular effects in people with T2DM. Ertugliflozin is still to report on this data. This document summarises the key prescribing considerations. NICE Technology Appraisal Recommendation NICE makes recommendations for when SGLT2 inhibitors can be considered in adults with T2DM; Hertfordshire Medicines Management Committee Recommendations are in line with NICE guidance: Monotherapy NICE TA 390: Canagliflozin, Dapagliflozin and Empagliflozin and NICE TA 572: Ertugliflozin as monotherapies for treating T2DM Monotherapy recommended as option in adults for whom metformin is contraindicated or not tolerated and when diet & exercise alone do not provide adequate glycaemic control, only if: •a DPP‑4 inhibitor would otherwise be prescribed and •a sulfonylurea or pioglitazone is not appropriate. Dual therapy NICE TA 315: Canagliflozin, NICE TA288: Dapagliflozin, TA 336: Empagliflozin, TA 572: Ertugliflozin as combination therapies for treating T2DM In a dual therapy regimen in combination with metformin is recommended as an option, only if: •a sulfonylurea is contraindicated or not tolerated or •the person is at significant risk of hypoglycaemia or its consequences. In combination with insulin NICE TA 315: Canagliflozin, NICE TA288: Dapagliflozin, TA 336: Empagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option.
    [Show full text]
  • Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research
    Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Garabedian, Laura Faden. 2013. Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11156786 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research A dissertation presented by Laura Faden Garabedian to The Committee on Higher Degrees in Health Policy in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Health Policy Harvard University Cambridge, Massachusetts March 2013 © 2013 – Laura Faden Garabedian All rights reserved. Professor Stephen Soumerai Laura Faden Garabedian Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research Abstract This dissertation consists of two empirical papers and one methods paper. The first two papers use quasi-experimental methods to evaluate the impact of universal health insurance reform in Massachusetts (MA) and Thailand and the third paper evaluates the validity of a quasi- experimental method used in comparative effectiveness research (CER). My first paper uses interrupted time series with data from IMS Health to evaluate the impact of Thailand’s universal health insurance and physician payment reform on utilization of medicines for three non-communicable diseases: cancer, cardiovascular disease and diabetes.
    [Show full text]
  • Pharmacoepidemiological Study Report Synopsis ER-9489 A
    DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Pharmacoepidemiological study report synopsis ER-9489 A retrospective nationwide cohort study to investigate the treatment of type 2 diAbetic pAtients in Finland - DAHLIA Authors: Solomon Christopher, Anna Lundin, Minna Vehkala, Fabian Hoti Study ID: ER-9489 Sponsor: AstraZeneca Nordic Baltic Report version: 1.0 Report date: 14 November 2017 EPID ReseArch CONFIDENTIAL DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Study Information Title A retrospective nationwide cohort study to investigate the treatment of type 2 diabetic patients in Finland – DAHLIA Study ID ER-9489 Report synopsis version 1.0 Report synopsis date 14 November 2017 EU PAS register number ENCEPP/SDPP/8202 Sponsor AstraZeneca Nordic Baltic SE-151 85 Södertälje, Sweden Sponsor contact person Susanna Jerström, Medical Evidence Manager Medical Nordic-Baltic SE-151 85 Södertälje, Sweden Active substance ATC codes A10 (Drugs used in diabetes) Medicinal product The folloWing AstraZeneca products are available on the Finnish market: Bydureon (exenatide A10BX04), Byetta (exenatide A10BX04), Forxiga (dapagliflozin A10BX09), Komboglyze (metformine and saxagliptin A10BD10), Onglyza (saxagliptin A10BH03), Xigduo (dapagliflozin and metformin A10BD15) Country of study Finland Authors of the report Solomon Christopher, Anna Lundin, Minna Vehkala, Fabian Hoti synopsis EPID ReseArch Page 2 of 43 DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Table of contents 1 Study report summary (Abstract) ...........................................................................................
    [Show full text]
  • (SGLT2) Inhibitors Reference Number: HIM.PA.91 Effective Date: 01.01.15 Last Review Date: 02.20 Line of Business: HIM Revision Log
    Clinical Policy: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Reference Number: HIM.PA.91 Effective Date: 01.01.15 Last Review Date: 02.20 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The following agents contain a sodium-glucose co-transporter 2 (SGLT2) inhibitor and require prior authorization: canagliflozin (Invokana®), canagliflozin/metformin (Invokamet®), dapagliflozin (Farxiga®), dapagliflozin/metformin (Xigduo® XR), empagliflozin (Jardiance®), empagliflozin/linagliptin (Glyxambi®), empagliflozin/linagliptin/metformin (TrijardyTM XR), and empagliflozin/metformin (Synjardy®). FDA Approved Indication(s) SGLT2 inhibitors are indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dapagliflozin-, canagliflozin-, and empagliflozin-containing products are also indicated in adult patients with type 2 diabetes mellitus and established cardiovascular disease (or multiple cardiovascular risk factors [dapagliflozin only]) to: Reduce the risk of hospitalization for heart failure (HF) (dapagliflozin) Reduce the risk of major adverse cardiovascular events: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (canagliflozin) Reduce the risk of cardiovascular death (empagliflozin) Canagliflozin-containing products are additionally indicated to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for HF in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria > 300 mg/day. Limitation(s) of use: SGLT2 inhibitors should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.
    [Show full text]